What's breaking now, across thousands of outlets.
Roivant Chief Executive Officer Matt Gline expects the FDA to approve the launch of a drug used to fight a debilitating skin disease. He says the drug should be on the market by September. He speaks on "Bloomberg Open Interest." (Source: Bloomberg)
We haven't written up this one. Bloomberg has the full story — the link below goes straight to it.
This, after the country has been condemned for the hundreds of healthcare units it has struck in Gaza after October 7, 2023
Intellia Therapeutics said it discovered a common link among the patients who faced the highest liver enzyme elevations after receiving its CRISPR gene editing treatment for ATTR amyloidosis.
Type 2 diabetes is associated with an increased risk of heart disease. Many people with type 2 diabetes are prescribed blood sugar-lowering medication to reduce this risk.
NYU Langone Health and Dana-Farber Cancer Institute built an oncology decision support platform to guide clinicians through treatment decisions.
One of the hallmarks of Alzheimer's disease is the accumulation of a peptide in the brain known as amyloid beta. A new study published in Nature Communications on July 22 has uncovered the atomic…
